Page last updated: 2024-11-03

pyrimethamine and Emesis

pyrimethamine has been researched along with Emesis in 10 studies

Maloprim: contains above 2 cpds

Research Excerpts

ExcerptRelevanceReference
"Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa."9.22Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016)
"Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1."9.07Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."8.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate."7.85Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017)
"The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children."7.67A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985)
" RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration."7.01Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023)
"Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa."5.22Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016)
"Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1."5.07Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991)
"The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity."4.98Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018)
"Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate."3.85Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017)
"The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children."3.67A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985)
" RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration."3.01Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023)
" No significant adverse event attributable to any of the study drugs was found."2.73Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19902 (20.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Muthoka, EN1
Usmael, K1
Embaye, SM1
Abebe, A1
Mesfin, T1
Kazembe, D1
Ahmedin, M1
Namuganza, S1
Kahabuka, M1
Atim, MG1
Manyazewal, T1
González, R2
Pons-Duran, C2
Piqueras, M2
Aponte, JJ2
Ter Kuile, FO3
Menéndez, C2
Kakuru, A1
Jagannathan, P1
Muhindo, MK1
Natureeba, P1
Awori, P1
Nakalembe, M1
Opira, B1
Olwoch, P1
Ategeka, J1
Nayebare, P1
Clark, TD1
Feeney, ME1
Charlebois, ED1
Rizzuto, G1
Muehlenbachs, A1
Havlir, DV1
Kamya, MR1
Dorsey, G1
Lee, SJ1
Price, RN1
Luxemburger, C2
Nosten, F2
Maiga, AS1
Diakite, M1
Diawara, A1
Sango, HA1
Coulibaly, CO1
Djimdé, AA1
Fofana, B1
Sagara, I1
Sidibe, B1
Toure, S1
Dembele, D1
Dama, S1
Ouologuem, D1
Dicko, A1
Doumbo, OK1
ter Kuile, F1
Chongsuphajaisiddhi, T1
Webster, HK1
Edstein, M1
Phaipun, L1
Thew, KL1
White, NJ1
Bradley-Moore, AM1
Greenwood, BM1
Bradley, AK1
Akintunde, A1
Attai, ED1
Fleming, AF1
Bartlett, A1
Bidwell, DE1
Voller, A1
Kirkwood, BR1
Lazar, M1
Weiner, MJ1
Leopold, IH1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167]Phase 42,500 participants (Anticipated)Interventional2023-11-06Recruiting
Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546]Phase 3340 participants (Actual)Interventional2020-08-31Completed
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447]Phase 3300 participants (Actual)Interventional2014-06-23Completed
A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218]Phase 35,920 participants (Actual)Interventional2017-04-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidence of Complicated Malaria in Infants

Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.022
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.024
3 Dose DP Pregnancy / Monthly DP Infancy0.000
Monthly DP Pregnancy / 3 Monthly DP Infancy0.035
Monthly DP Pregnancy / Monthly DP Infancy0.000

Incidence of Hospital Admissions in Infants

Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.043
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.036
3 Dose DP Pregnancy / Monthly DP Infancy0.089
Monthly DP Pregnancy / 3 Monthly DP Infancy0.082
Monthly DP Pregnancy / Monthly DP Infancy0.043

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.87
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.88
3 Dose DP Pregnancy / Monthly DP Infancy0.83
Monthly DP Pregnancy / 3 Monthly DP Infancy1.24
Monthly DP Pregnancy / Monthly DP Infancy0.64

Incidence of Malaria in Infants

Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)

InterventionEvents per person years (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy0.26
3 Dose DP Pregnancy / 3 Monthly DP Infancy0.30
3 Dose DP Pregnancy / Monthly DP Infancy0.00
Monthly DP Pregnancy / 3 Monthly DP Infancy0.43
Monthly DP Pregnancy / Monthly DP Infancy0.03

Incidence of Malaria in Pregnant Women

Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination

Interventionevents per person years (Number)
Mothers - 3 Dose SP0.95
Mothers - 3 Dose DP0.31
Mothers - Monthly DP0

Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery

Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP19
Mothers - 3 Dose DP19
Mothers - Monthly DP9

Prevalence of Anemia in Pregnant Women

Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination

Interventionhemoglobin measurements taken every 12wk (Number)
Mothers - 3 Dose SP94
Mothers - 3 Dose DP72
Mothers - Monthly DP61

Prevalence of Gametocytemia in Infants

Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy7
3 Dose DP Pregnancy / 3 Monthly DP Infancy1
3 Dose DP Pregnancy / Monthly DP Infancy0
Monthly DP Pregnancy / 3 Monthly DP Infancy4
Monthly DP Pregnancy / Monthly DP Infancy0

Prevalence of Gametocytemia in Pregnant Women

Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery

InterventionPositive blood smears (Number)
Mothers - 3 Dose SP4
Mothers - 3 Dose DP1
Mothers - Monthly DP3

Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy

Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination

InterventionPositive specimens (Number)
Mothers - 3 Dose SP206
Mothers - 3 Dose DP74
Mothers - Monthly DP26

Prevalence of Parasitemia in Infants

Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination

InterventionPositive blood smears (Number)
3 Dose SP Pregnancy / 3 Monthly DP Infancy59
3 Dose DP Pregnancy / 3 Monthly DP Infancy25
3 Dose DP Pregnancy / Monthly DP Infancy7
Monthly DP Pregnancy / 3 Monthly DP Infancy52
Monthly DP Pregnancy / Monthly DP Infancy4

Prevalence of Placental Malaria

Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery

InterventionParticipants (Count of Participants)
Mothers - 3 Dose SP49
Mothers - 3 Dose DP30
Mothers - Monthly DP26

Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP

Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery

,,
InterventionParticipants (Count of Participants)
Micropscopic assessment of placental bloodLAMP assessment of placental blood
Mothers - 3 Dose DP33
Mothers - 3 Dose SP519
Mothers - Monthly DP02

Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery

Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery

,,
Interventionparticipants (Number)
MicroscopyLAMP
Mothers - 3 Dose DP13
Mothers - 3 Dose SP525
Mothers - Monthly DP01

Incidence of Clinical Episodes of Malaria

Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.

InterventionNo. of events/1000 person years at risk (Number)
SMC With SP+AQ304.8
RTS,S/AS01278.2
RTS,S/AS01 PLUS SMC With SP+AQ113.3

Reviews

3 reviews available for pyrimethamine and Emesis

ArticleYear
Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials.
    Malaria journal, 2023, Oct-21, Volume: 22, Issue:1

    Topics: Antimalarials; Drug Combinations; Female; Humans; Infant; Malaria; Pregnancy; Pregnancy Complication

2023
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 03-21, Volume: 3

    Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug

2018
Mefloquine for preventing malaria in pregnant women.
    The Cochrane database of systematic reviews, 2018, 11-14, Volume: 11

    Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum

2018

Trials

4 trials available for pyrimethamine and Emesis

ArticleYear
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
    The New England journal of medicine, 2016, Mar-10, Volume: 374, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D

2016
[Pharmacovigilance and impact of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women in Sélingué, Mali].
    Le Mali medical, 2010, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Endemic D

2010
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
    The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:3

    Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R

2008
Mefloquine-resistant falciparum malaria on the Thai-Burmese border.
    Lancet (London, England), 1991, May-11, Volume: 337, Issue:8750

    Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Drug Resist

1991

Other Studies

3 other studies available for pyrimethamine and Emesis

ArticleYear
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Anorexia; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dizzi

2017
A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, Volume: 79, Issue:5

    Topics: Antibodies; Chloroquine; Enzyme-Linked Immunosorbent Assay; Ferritins; Folic Acid; Hemodynamics; Hum

1985
Treatment of uveitis with methotrexate.
    American journal of ophthalmology, 1969, Volume: 67, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Alopecia; Anti-Bacterial Agents; Child;

1969